LOROCSON study: Late Onset Recurrent Ovarian Cancer: Surgery Or Not.

A randomized phase III study for the treatment of recurrent epithelial ovarian cancer: chemotherapy alone versus chemotherapy followed by secondary cytoreductive surgery in patients with a disease-free interval of more than 6 months.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON27781

Enrollment

700

Registered

2005-10-13

Start date

2005-10-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

After registration the patient will immediately start the first course of chemotherapy. After the induction chemotherapy the response to therapy will be evaluated. In case of progressive disease the p

Eligibility

Inclusion criteria

Inclusion criteria: Recurrence of epithelial ovarian cancer, after first line chemotherapy with a disease-free interval of at least 6 months, age> 18 years, WHO Performance status 0-2. The first-line therapy should have consisted of at least 4 courses of either cisplatin or carboplatin.

Exclusion criteria

Exclusion criteria: More than one line chemotherapy, complete bowel obstruction, metastasized carcinoma (other tumor), leptomeningeal or brain metastases.

Design outcomes

Primary

Measure	Time frame
Progression-free survival.	—

Secondary

Measure	Time frame
Survival, toxicity, surgical treatment related complications and quality of life.	—

Contacts

Public ContactP.M.L.H. Vencken

Erasmus Medical Center, Department Obstetrics and Gynecology, Dr. Molewaterplein 60

p.vencken@erasmusmc.nl / pvencken@hotmail.com+31 (0)10 4636363

Outcome results